Ponatinib is a targeted medicine which treats leukemia conditions. Moreover, it is used for chronic myeloid and Philadelphia chromosome-positive leukemias. Also, doctors suggest attending consistent genetic testing to aid in treatment. On the other hand, it unlocks precision medicine, which helps to avoid severe side effects.
What is chronic myeloid leukemia?
Chronic myeloid leukemia is a slow-growing blood and bone marrow cancer. These cancerous DNA chromosomes swap places. Moreover, this causes gene changes and produces a protein. Also, it increases immature white blood cells in the body. Therefore, it crowds healthy red blood cells, white blood cells, and platelets.
What Is the Philadelphia Chromosome?
The Philadelphia chromosome is known as an abnormal and shortened chromosome. Also, this is found in some leukemia patients with genetic mix-ups. Furthermore, the pieces of chromosomes 9 and 22 break off and trade places. Thus, causing an abnormal fusion which causes rapid growth of cancer cells.
What Is Ponatinib?
Ponatinib is a tyrosine kinase inhibitor. Moreover, it blocks proteins which drive cancer growth. This decreases cancer progression and spread in the body. Also, the patient takes the tablet once daily with or without food and swallows it whole.
How Does Ponatinib Work?
It works by blocking the BCR-ABL protein, which increases blood cancer growth. Also, a faulty Philadelphia chromosome produces these proteins. Moreover, the protein constantly sends growth signals to cancer cells. Thus, this blocking can stop the cancer cells from growing. In addition, cancer cells starve and die off slowly.
Benefits of Ponatinib Therapy
There are certain benefits, like:
- Stops cancer growth
- Decrease cancer progression
- Reduce cancer load
- Shrink the tumor
What are the brands?
Why Is Genetic Testing Important?
Genetic testing helps to determine specific gene mutations and gene conditions. Furthermore, it can aid in disease prevention, early detection and effective medicines. Also, this ensures family planning decisions.
There are major benefits of testing. They are:;
- Discover T315I “Gatekeeper” Mutation
- Treatment-specific dosage
- Monitor Minimal Residual Disease
- Treating Treatment Resistance
- Toxic control
- Targeting Other Rare Cancers
What are the Ponatinib uses?
The different conditions are as follows:
- Chronic Myeloid Leukemia
- Acute lymphoblastic leukemia
- Philadelphia Chromosome-Positive Leukemia
Ponatinib and Precision Oncology
Ponatinib is a mutation-matched precision drug which overcomes resistance to earlier therapies. Also, precision therapy targets the DNA signature, genes, and molecules of tumor. Moreover, the medicine can also block the T315I mutation. The precision target of this medicine is also the KIT-mutant melanoma and FGFR changes.
Interaction with other medicines
Ponatinib can cause high blood pressure and nausea. Therefore, doctors suggest medicines to manage side effects. Moreover, it is also used with certain chemotherapy medicines to increase effects. On the other hand, before combining medicines, always consult with your doctor.
Conclusion
The medicine is responsible for treating multiple types of leukemia. Moreover, it can block specific proteins and gene mutations. Also, this can aid in cancer growth and division. However, after blocking, cancer cells starve from growth signals and cause cell death. In addition, doctors use different combinations to treat conditions. Therefore, this targeted medicine becomes reliable for patients.
FAQs
Why does this medicine cause swelling of the pancreas?
It can disrupt pancreatic function by releasing calcium. Moreover, when the balance is disturbed, digestive enzymes can damage tissues and cause swelling.
Why is precision medicine essential?
It can help patients to reduce side effects and increase treatment efficacy. Furthermore, doctors use targeted therapies to target tumor. On the other hand, it can avoid using chemotherapies which kill all rapid dividing cells.
Reference
- Massaro, F., Molica, M., & Breccia, M. (2018). Ponatinib: a review of efficacy and safety. Current cancer drug targets, 18(9), 847-856. https://www.ingentaconnect.com/content/ben/ccdt/2018/00000018/00000009/art00004
- Miller, G. D., Bruno, B. J., & Lim, C. S. (2014). Resistant mutations in CML and Ph+ ALL–role of ponatinib. Biologics: Targets and Therapy, 243-254. https://www.tandfonline.com/doi/full/10.2147/BTT.S50734
- Chan, O., Talati, C., Isenalumhe, L., Shams, S., Nodzon, L., Fradley, M., … & Pinilla-Ibarz, J. (2020). Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood advances, 4(3), 530-538. https://ashpublications.org/bloodadvances/article/4/3/530/441050/Side-effects-profile-and-outcomes-of-ponatinib-in
- Jabbour, E., Short, N. J., Ravandi, F., Huang, X., Daver, N., DiNardo, C. D., … & Kantarjian, H. (2018). Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. The Lancet Haematology, 5(12), e618-e627. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00319-2/abstract
- Kantarjian, H. M., Chifotides, H. T., Haddad, F. G., Short, N. J., Loghavi, S., & Jabbour, E. (2024). Ponatinib‐review of historical development, current status, and future research. American journal of hematology, 99(8), 1576-1585. https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27355
